Cyclic peptides cross cell membranes by switching between an open conformation in water and a closed conformation in lipid, a behavior called the chameleon switch. A 2023 molecular dynamics study models the crossing as four sequential steps, from side-chain anchoring to lower-leaflet exit, and…
Cyclic peptides cross cell membranes by switching molecular shape in response to their environment. In water, they open up and expose polar groups to the solvent. In the oily interior of a lipid bilayer, they close into a compact form that hides those same polar groups behind intramolecular hydrogen bonds. This conformational plasticity, called chameleon behavior , is the mechanism that lets a cyclic peptide be soluble enough to reach a membrane and greasy enough to pass through it. The switch, and the four-step crossing process that follows from it, are the central design handles for improving the oral bioavailability of peptide drugs.
The practical stakes are plain. Most peptides are digested in the gut and cannot pass through intestinal cell membranes, which is why nearly all peptide therapeutics are injected. Cyclosporine A broke that pattern. The natural cyclic peptide demonstrated high oral bioavailability in 1983 and was developed as an oral formulation, and it remains the reference example of what a cyclic scaffold can achieve. The 1980s were the decade in which oral peptide delivery research began in earnest, with 1983 as the key date. Since then the field has worked two problems in parallel: resistance to enzymatic degradation and crossing the cell membrane. A molecular dynamics study published in 2023 by Stephanie Linker and colleagues addresses the second problem, modeling a flexible decacyclic peptide crossing a lipid bilayer in four discrete steps.
Why linear peptides fail at membranes is a matter of hydrogen-bond accounting. A straight-chain peptide in solution populates many similar extended states, and its backbone amide groups remain available to hydrogen bond with water. Moving into a lipid bilayer carries a steep cost: every polar atom that sheds its water shell before entering the membrane interior must pay a desolvation energy penalty. With a full set of backbone amides exposed, the bill is too high for efficient passage. Cyclic peptides escape this trap through controlled flexibility. Because the backbone is closed into a ring, the molecule can fold into compact shapes a linear chain cannot hold, and some of those shapes hide the polar backbone entirely.
The chameleon behavior is a response to environmental polarity. In polar media such as blood or cytoplasm, the peptide adopts an open conformation with hydrogen-bonding atoms exposed to the solvent. In nonpolar media such as the membrane interior, it adopts a closed conformation , burying polar groups behind intramolecular hydrogen bonds and exposing nonpolar groups to the surrounding lipid. The chameleon analogy is exact in one respect: the change is reversible and driven by competition for hydrogen bonds. Water competes for backbone amides, so in aqueous environments the open form is favored. In a lipid environment there is no competing solvent, so the amides hydrogen bond with one another and the molecule collapses into the closed state.
The closed conformation lowers the desolvation energy by reducing the polar surface area of the molecule. Fewer polar atoms in contact with the membrane interior means a smaller penalty for leaving water behind. Because the switch balances water solubility against fat solubility, it improves cell permeability, and this balance is the basis of the value of cyclic peptides for oral formulation. It is also a balance, not a single target state. The closed state is generally considered the main permeability state, but the switch is dynamic, and it is influenced by sequence, molecular size, and hydrophobic surface area. A molecule that closes too readily will not dissolve in the gut lumen. A molecule that cannot close will never enter the membrane in the first place. The oral candidates that work sit between the two, and rational design aims to place them there.
The most detailed account of the crossing event comes from simulation, because the event itself is difficult to observe directly. A lipid bilayer is only a few nanometers thick, and the conformational change of interest happens on timescales of nanoseconds. Linker and colleagues performed molecular dynamics simulations of a flexible decacyclic peptide , a cyclic peptide with a ten-residue ring, crossing a lipid bilayer. The study appeared in the Journal of Medicinal Chemistry in 2023, 66 4 , pages 2773-2788. Three figures carry the essential material of this account. Fig. 1 is the chemical structure of cyclosporine A, the natural product that proved oral cyclic peptides were possible. Fig. 2 is the structure of the flexible decacyclic peptide used in the simulations. Fig. 3 is the four-step process of passive membrane penetration by flexible cyclic peptides.
Step one is anchoring . Specific peptide side chains attach the peptide to the membrane surface before any insertion begins. The simulations show that the anchor residues differ between open and closed conformations, because the contact a residue makes with the membrane is not the same in the two shapes. A side chain that is exposed in one conformation may be buried in the other, so the identity of the anchoring residue depends on which state the peptide is in when it reaches the membrane. A design that assumes the wrong conformation will pick the wrong anchor.
Step two is insertion . The peptide lies down parallel to the membrane plane rather than entering end first. Peptides in the open conformation can insert in either of two orientations, A or B. Peptides already in the closed conformation insert only in orientation B. The asymmetry is a design constraint: only orientation B favors the transition from open to closed conformation. For macrocyclic peptides with continuous hydrophobic surfaces, orientation B is the relevant design case, and peptide candidates that insert only in orientation A will not proceed efficiently through the rest of the permeation process.
Step three is the open-to-closed transition . The conformational change is the critical step for subsequent diffusion through the membrane interior. The closed form has the smaller polar surface area, pays the lower desolvation penalty, and diffuses more efficiently through the hydrocarbon core. A peptide that cannot close once inside the bilayer will move slowly and may stall partway across.
Step four is exit . To complete membrane crossing, the peptide anchors to the polar head region of the lower leaflet and reverses direction, which changes the direction of its hydrophobic moment . The molecule then emerges on the far side of the bilayer. The four steps, with their principal findings, are summarized below.
| Step | Event in the simulation | Key finding |
| --- | --- | --- |
| 1 | Side-chain anchoring to the membrane surface | Anchor residues differ between open and closed conformations |
| 2 | Insertion parallel to the membrane plane | Open peptides insert in orientation A or B; closed peptides in B only |
| 3 | Open-to-closed conformational transition | Critical step for diffusion through the membrane interior |
| 4 | Anchoring to the lower leaflet and direction reversal | Hydrophobic moment reverses direction to complete exit |
Read as a sequence, the model describes a molecule feeling its way across the bilayer: contact by side chains, orientation on the surface, collapse to a diffusable shape in the middle, and reorientation at the far side. Each step is a gate. Fail to anchor, insert in the wrong orientation, fail to close, or fail to reorient, and the peptide does not cross.
None of these steps is a direct experimental observation. The four-step model comes from molecular dynamics simulations, so it is best read as a mechanistic hypothesis, not a measured record of a peptide crossing a bilayer. Simulations are strongest when they expose the energetic logic of a process that is hard to image, and this model is consistent with the general behavior of chameleon peptides and with the historical example of cyclosporine A. What it is not is pharmacokinetic evidence. The study does not report quantitative bioavailability data, and this topic's literature provides no measured figures beyond cyclosporine A.
Two cautions follow for anyone using this work in design. First, the closed state is generally considered the main permeability state, but permeability is a dynamic process controlled by multiple interdependent factors. The population of conformations before membrane contact, the rate of switching between them, and the depth of the desolvation penalty all matter, and none of them is captured by a single snapshot of the closed form. Second, residue-level rules do not transfer cleanly between peptides. The contribution of amino acids such as leucine, phenylalanine, and proline depends on their position and their neighboring residues, not on the residue alone. An anchoring residue in one sequence may be a bystander in another, so substitution rules derived from one peptide should not be extrapolated to the next without testing.
The report describing the study also generalizes the anchoring mechanism beyond peptides. The early event in permeation is, at bottom, a hydrophobic contact between flexible side chains and the bilayer surface. Adding moderate aliphatic chains to a molecule of another class could in principle mimic that anchoring step and improve membrane permeability. This is a testable proposition, and it is the clearest route by which cyclic peptide results might inform non-peptide drug design. It is also, for now, a proposition without experimental confirmation, so it should be read as a hypothesis from the authors rather than a measured result.
Oral bioavailability is a two-part problem. A peptide must survive gastrointestinal and serum proteases, and it must cross the intestinal epithelium into the blood. The chameleon switch and the four-step model address the crossing part. They do nothing for enzymatic stability, and effective oral peptide delivery requires solving both. The simulation results are best used as one input to that broader design cycle, not as a complete recipe.
Within the crossing problem, the model supports a set of concrete rules. They apply at different stages of a discovery program, from scaffold choice at the design stage to conformational analysis before synthesis. A researcher screening scaffolds, sequences, or conjugation strategies can apply them directly.
Two of these rules carry most of the practical weight. The first is the orientation constraint. A candidate that inserts only in orientation A will not make the open-to-closed transition and will diffuse poorly through the membrane interior. Screening in silico for the ability to populate orientation B, before committing to synthesis, is a feasible step that follows directly from the model. The second is the conformational census. Building a small ensemble of low-energy conformations in water and in a low-dielectric environment, then asking which residues are solvent-exposed in each, is the fastest way to identify candidate anchor residues. The simulation result that anchor identity changes with conformation makes this census a necessary step rather than an optional refinement.
The same logic applies to synthesis decisions. A candidate whose closed state is too stable will lack aqueous solubility; one whose open state is too stable will lack permeability. The chameleon balance is a measurable property. Comparing computed polar surface area between the two states, and checking the desolvation penalty of the membrane-facing surface, gives a quick read on whether a candidate sits in the useful middle range. These checks do not guarantee oral bioavailability, which depends on enzymatic stability, uptake mechanisms, and first-pass metabolism, but they address the specific barrier the model describes.
Cyclosporine A remains the exception that defines the problem. It is a natural product with an unusual structure, and its oral bioavailability has not been replicated by molecules designed from chameleon principles. How to achieve high oral bioavailability for peptides beyond cyclosporine A is still an open question, and the historical example does not by itself supply a design rule.
The other open questions follow the gaps in the model. Which sequence positions and residue combinations most effectively drive anchoring and lower-leaflet exit? The simulations identify the steps but not the optimal residues for each one. What design rules reliably control the open-to-closed conformational switch in different membrane environments? The switch is known to depend on sequence, size, and hydrophobic surface area, but no quantitative rule predicts where a given sequence will sit on that balance in a given membrane. How well do the cyclic peptide insights generalize to other molecular modalities? Aliphatic chain conjugation is a plausible mimic of side-chain anchoring, but it has not been demonstrated in a pharmacokinetic setting. The deepest question is experimental: can the simulation-based mechanism be validated in living systems and translated into approved oral peptide drugs? Direct observation of the open-to-closed transition inside a bilayer remains beyond current experimental techniques.
The goal of this line of research is worth stating plainly. It is to improve oral bioavailability and enable more orally deliverable peptide drugs. The chameleon switch explains why cyclosporine A worked. The four-step model explains what a successful candidate must do at the membrane. The distance between those explanations and a new oral peptide drug is still measured in unresolved design rules, and the best available response is to treat the model as a guide to what to measure, not as a promise of what will work.
Related reading: Enzymatic Routes to Short Peptides: Mechanisms, Uses, Limits, Antitumor Peptides: Mechanisms, Production, and Applications, Neoantigen Peptide Synthesis Services and GMP Manufacturing, How Chameleon Cyclic Peptides Cross Membranes for Oral Drugs.